The major barrier to eradicate HIV-1 is its persistence in latently infected cells. Inducing deep latency to prevent HIV-1 reactivation in the absence of combined antiretroviral therapy (cART) remains Show more
The major barrier to eradicate HIV-1 is its persistence in latently infected cells. Inducing deep latency to prevent HIV-1 reactivation in the absence of combined antiretroviral therapy (cART) remains a primary goal. Here, we evaluated the repurposing of lithium as an HIV-1 latency-promoting drug (LPA). We demonstrated that lithium attenuates virus reactivation in three cell models for HIV-1 latency. Lithium induced autophagy in CD4 Show less